High-flow medical oxygen insufflation
ApprovedSmall molecule
High-flow medical oxygen insufflation is one of 11 small molecule programs targeting Hypoxemia. It is currently in Approved.
1
Indications
1
Total Trials
1
Active Trials
10
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
15 competitors in Hypoxemia
#DrugCompanyPhaseTrials
1Esmeron
FFresenius Kabi Oncology Ltd.
Approved
Inomax
MMallinckrodt
Approved
Narcan
SScienture
Phase 3
Standard Treatment
Boehringer IngelheimPhase 3
Inhaled Prostacyclin
United TherapeuticsPhase 2
High-flow medical oxygen insufflation
OOutcomes'10
Approved
Cetirizine Hcl
Mylan Pharmaceuticals IncApproved
Frespaciguat
Merck & Co.Phase 1
Inhaled Nitric Oxide
LLee's Pharmaceutical Limited
Preclinical
Antihypertensive Agents
NNational Heart, Lung, and Blood Institute (NHLBI)
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Approved[1]
- Company
- OOutcomes'10